Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.

[1]  T. Kwast,et al.  Urine markers for bladder cancer surveillance: a systematic review. , 2005 .

[2]  G. Bartsch,et al.  628Voided urinary specimen-comparison of a multitarget in situ hybridisation fluorescence (fish) assay, NMP22-bladderchek© and conventional cytology for detection of transitional cell cancer of the bladder , 2005 .

[3]  H. Huland,et al.  630The new proteomic-based point-of-care (POC) urine NMP22-bladder.chek® compared to the standard NMP22-elisa urine lab test for bladder cancer detection , 2005 .

[4]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[5]  K. Tomera.  NMP22® BladderChek® Test: point-of-care technology with life- and money-saving potential , 2004, Expert review of molecular diagnostics.

[6]  J. Palou,et al.  380 The detection of nuclear matrix protein 22 in the follow up of patients after endovesical treatment with BCG , 2004 .

[7]  Marije Deutekom,et al.  Tumor markers in the diagnosis of primary bladder cancer. A systematic review. , 2003, The Journal of urology.

[8]  H. Ozen,et al.  False-positive results of the NMP22 test due to hematuria. , 2002, The Journal of urology.

[9]  A. Agarwal,et al.  Screening and monitoring for bladder cancer: refining the use of NMP22. , 2001, The Journal of urology.

[10]  M. Soloway,et al.  Current bladder tumor tests: does their projected utility fulfill clinical necessity? , 2001, The Journal of urology.

[11]  F. M. Brown,et al.  URINE CYTOLOGY: Is it Still the Gold Standard for Screening? , 2000 .

[12]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[13]  Koss Lg.  Errors and pitfalls in cytology of the lower urinary tract. , 1997 .

[14]  K Koiso,et al.  Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. , 1997, European urology.

[15]  E. Messing,et al.  Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. , 1996, The Journal of urology.

[16]  L. Kiemeney,et al.  Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. , 1993, The Journal of urology.

[17]  A B West,et al.  Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. , 1986, The Journal of urology.

[18]  L. Koss,et al.  Interobserver and intraobserver differences in the diagnosis of urothelial cells. Comparison with classification by computer. , 1984, Analytical and quantitative cytology.

[19]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.